Ghent University Academic Bibliography

Advanced

Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems

Koen Boussery UGent, Julie De Smet UGent, Pieter De Cock UGent, SASKIA VANDE VELDE UGent, Els Mehuys UGent, Peter De Paepe UGent, Jean Paul Remon UGent, Jan Van Bocxlaer UGent and Myriam Van Winckel UGent (2011) BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 72(6). p.990-996
abstract
AIMS Omeprazole is often administered through a gastrostomy tube as either (i) a Multiple Unit Pellet System (MUPS (R)) tablet disintegrated in water (MUPS (R) formulation), or (ii) a suspension in 8.4% sodium bicarbonate (suspension formulation). This bioavailability study evaluates this practice in tube-fed patients with severe neurodevelopmental problems. METHODS Nonblinded, two-phase cross-over trial. RESULTS In seven of 10 patients, bioavailability was higher for the suspension formulation than for the MUPS (R) formulation. Median (90% confidence interval) area under the plasma concentration-time curve ratio (MUPS (R) over suspension) was 0.5 (0.06-2.37). CONCLUSIONS In this population, omeprazole MUPS (R) formulation has no apparent advantage over the more easily administered suspension formulation.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
PROTON PUMP INHIBITORS, CHILDREN, proton pump inhibitor, omeprazole, neurodevelopmental problem, feeding tube, cerebral palsy, bioavailability, SINGLE, LANSOPRAZOLE, THERAPY
journal title
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Br. J. Clin. Pharmacol.
volume
72
issue
6
pages
990 - 996
Web of Science type
Article
Web of Science id
000296901900018
JCR category
PHARMACOLOGY & PHARMACY
JCR impact factor
2.958 (2011)
JCR rank
81/259 (2011)
JCR quartile
2 (2011)
ISSN
0306-5251
DOI
10.1111/j.1365-2125.2011.04038.x
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2137716
handle
http://hdl.handle.net/1854/LU-2137716
date created
2012-06-08 16:21:42
date last changed
2012-06-25 09:14:16
@article{2137716,
  abstract     = {AIMS Omeprazole is often administered through a gastrostomy tube as either (i) a Multiple Unit Pellet System (MUPS (R)) tablet disintegrated in water (MUPS (R) formulation), or (ii) a suspension in 8.4\% sodium bicarbonate (suspension formulation). This bioavailability study evaluates this practice in tube-fed patients with severe neurodevelopmental problems. 
METHODS Nonblinded, two-phase cross-over trial. 
RESULTS In seven of 10 patients, bioavailability was higher for the suspension formulation than for the MUPS (R) formulation. Median (90\% confidence interval) area under the plasma concentration-time curve ratio (MUPS (R) over suspension) was 0.5 (0.06-2.37). 
CONCLUSIONS In this population, omeprazole MUPS (R) formulation has no apparent advantage over the more easily administered suspension formulation.},
  author       = {Boussery, Koen and De Smet, Julie and De Cock, Pieter and VANDE VELDE, SASKIA and Mehuys, Els and De Paepe, Peter and Remon, Jean Paul and Van Bocxlaer, Jan and Van Winckel, Myriam},
  issn         = {0306-5251},
  journal      = {BRITISH JOURNAL OF CLINICAL PHARMACOLOGY},
  keyword      = {PROTON PUMP INHIBITORS,CHILDREN,proton pump inhibitor,omeprazole,neurodevelopmental problem,feeding tube,cerebral palsy,bioavailability,SINGLE,LANSOPRAZOLE,THERAPY},
  language     = {eng},
  number       = {6},
  pages        = {990--996},
  title        = {Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems},
  url          = {http://dx.doi.org/10.1111/j.1365-2125.2011.04038.x},
  volume       = {72},
  year         = {2011},
}

Chicago
Boussery, Koen, Julie De Smet, Pieter De Cock, Saskia Vande Velde, Els Mehuys, Peter De Paepe, Jean Paul Remon, Jan Van Bocxlaer, and Myriam Van Winckel. 2011. “Pharmacokinetics of Two Formulations of Omeprazole Administered Through a Gastrostomy Tube in Patients with Severe Neurodevelopmental Problems.” British Journal of Clinical Pharmacology 72 (6): 990–996.
APA
Boussery, K., De Smet, J., De Cock, P., Vande Velde, S., Mehuys, E., De Paepe, P., Remon, J. P., et al. (2011). Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 72(6), 990–996.
Vancouver
1.
Boussery K, De Smet J, De Cock P, Vande Velde S, Mehuys E, De Paepe P, et al. Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2011;72(6):990–6.
MLA
Boussery, Koen, Julie De Smet, Pieter De Cock, et al. “Pharmacokinetics of Two Formulations of Omeprazole Administered Through a Gastrostomy Tube in Patients with Severe Neurodevelopmental Problems.” BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 72.6 (2011): 990–996. Print.